Solid tumor events and webinars

New frontiers in biomarker testing and cancer patient profiling

Biomarker testing has the potential to support both the diagnosis and monitoring of solid tumors, with the possibility to facilitate targeted treatments for individual patients. To realize that potential, testing must use the right sample type, for the right biomarker and at the right time. So, how do we achieve this? Watch Prof. Umberto Malapelle of the University Federico II of Naples, Italy explore solid tumor biomarker testing and how new technologies are driving this forward.

Impact of molecular testing in patients with solid tumors

In this insightful presentation from Dr. Ernest Nadal of the Catalan Institute of Oncology (ICO), Barcelona, Spain, you will hear about the effect molecular testing has on real-world clinical cases of patients with solid tumors.

Expert panel discussion: From research to clinics – what's next for KRAS?

Experts Dr. Pascale Morel (QIAGEN), Prof. Umberto Malapelle (University Federico II of Naples, Italy) and Dr. Ernest Nadal (Catalan Institute of Oncology, Barcelona, Spain) discuss advances in KRAS testing in solid tumors and contemplate future progress.

Biomarker testing in NSCLC

Prof. Tae-Jung Kim of Yeouido St. Mary's Hospital, College of Medicine in Seoul, Korea, discusses clinical cases and the pros and cons of testing for single biomarkers vs multiple biomarkers.

Case study: resistance to osimertinib in patients with EGFR-mutated NSCLC

Join Dr. Marc Denis of the Plateforme de Génétique Moléculaire des Cancers, CHU - Hôtel-Dieu, Nantes, France, for a deep dive into osimertinib resistance in a patient whose non-small cell lung cancer harbors EGFR mutations.

Roundtable with patients: Access and perspective – advancing patient care

Join Dr. Pascale Morel (QIAGEN), Dr. Egbert Schulz (patient and head of a diagnostics laboratory), Ms. Lisa Alderson (patient) and Dr. Marc Denis (oncologist) for an enlightening discussion of two patients' perspectives of biomarker testing in solid tumors.

Biomarker testing using digital PCR: New horizons in cancer diagnostics

Digital PCR (dPCR) has revolutionized PCR-based testing, enabling the detection of rare targets in high background of non-target DNA with very high precision. Join Prof. Hsian-Rong Tseng, Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, David Geffen School of Medicine at UCLA, Los Angeles, USA, as he shares his insights into applying these benefits to biomarker testing in solid tumors and other cancers.

Roundtable: Companion diagnostics for biomarker profiling – a pharma perspective

Join Aaron Jordan (QIAGEN), Lee-Anne Zinetti (Senior Director, Global Precision Medicine, Novartis) and Prof. Umberto Malapelle (University Federico II of Naples, Italy) for this lively discussion about the roles of and relationships between pharma companies, academia and the companion diagnostic development partner in developing new drugs and IVD tests.

Comprehensive genomic profiling to interrogate DNA alterations using NGS

Watch Dr. Laura Lahtinen (Keski-Suomen Sairaala Nova Patologia, Jyväskylä, Finland) discuss the use of NGS technologies in solid tumor testing.

Using multimodal chemistry to test neurological tumor samples

Dr. Barnaby Clark from King's College Hospital, Denmark Hill, London, UK discusses his laboratory's work using next-generation sequencing in the molecular testing of brain cancers.

Expert panel: New horizons with digital PCR and NGS

Advances in next-generation sequencing (NGS) and digital PCR (dPCR) are breaking new ground in biomarker testing for patients with solid tumors. Join expert panelists, Dr. Mehdi Motallebipour (QIAGEN) Prof. Hsian-Rong Tseng, Dr. Laura Lahtinen and Dr. Barnaby Clark, as they discuss the latest insights in solid tumor biomarker testing with dPCR and NGS.

Flexible, sensitive EGFR mutation testing in NSCLC

Join Scott Markland to learn about the role of EGFR in non-small cell lung cancer, including the changing mutational landscape of EGFR testing in response to treatment with targeted therapies. Then, discover how testing with the therascreen EGFR Plus RGQ PCR Kit can benefit you and your NSCLC patients.

KRAS G12C in lung cancer treatment decisions

Dr. Anjen Chenn discusses the importance of testing for KRAS G12C in non-small cell lung cancer (NSCLC) patients in order to prescribe the targeted therapy LUMAKRAS.

Accelerate your NGS workflows

In this webinar with Krishna Amin (QIAGEN), learn how advances in QIAseq chemistry can help accelerate your NGS workflows.

Comparison of methods in routine somatic diagnostics

Dr. Mattia Schmid from UniLabs, Switzerland compares the methods of molecular oncology testing used in his laboratory and shows the results from a trial of a new method.

HRR and HRD: The role of DNA damage repair

Join Dr. Raed Samara and Dr. Vikas Gupta to explore the role of homogous recombination repair and deficiency in DNA damage repair.

Comprehensive genomic profiling or targeted NGS panels – a place for both?

Join Dr. Andrea Ferreira-Gonzalez, Dr. Ravindra Kolhe, Dr. Pauline Rehal, Dr. Peter Wild and Dr. Davide Manissero (Moderator) for this interesting and insightful panel discussion.